Heart failure & cardiomyopathiesResearch article
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis
- Review (meeting proceedings)
Amyloidosis Forum hybrid meeting on imaging endpoints in clinical trials
Authors' conclusion
This review summarizes the proceedings of the Amyloidosis Forum.
Study context
- Population
- Systemic AL and ATTR amyloidosis, with a focus on cardiac amyloidosis
Main finding
As reported in the abstract
Use of imaging endpoints in clinical trials for AL and ATTR amyloidosis (focus on cardiac amyloidosis)
- Stakeholders from academia, industry and multiple regulatory agencies reviewed the use of imaging biomarkers with a focus on cardiac amyloidosis
- Applications and limitations of imaging in clinical trials described
- Qualification of imaging as a surrogate clinical outcome discussed
- Survey results provided important patient perspectives
Original publication
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis. JACC Cardiovasc Imaging. Published 21 February 2025. doi:10.1016/j.jcmg.2024.11.003
Summarised from the published abstract; every number is checked against it